{"entity":{"id":"nct07465835","kind":"trial","name":"A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)","aka":[],"tldr":"A phase 1 trial of Ipsoprubart run by Electra Therapeutics Inc., now recruiting.","summary":"A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs) is a phase 1 interventional study registered as NCT07465835 by Electra Therapeutics Inc., with 84 participants planned, started 2026-02-17, primary completion expected 2028-06. Conditions recorded: T Cell Malignancies. Interventions recorded: ELA026.","status":"recruiting","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT07465835","url":"https://clinicaltrials.gov/study/NCT07465835"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["ipsoprubart"],"companies":["electra-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07465835","phase":"1","setting":"A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)","sponsor":"Electra Therapeutics Inc.","enrolled":84,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07465835/","neighbours":{"drug":[{"id":"ipsoprubart","kind":"drug","name":"Ipsoprubart","route":"/drugs/ipsoprubart/"}],"company":[{"id":"electra-therapeutics","kind":"company","name":"Electra Therapeutics","route":"/companies/electra-therapeutics/"}]}}